Effects of anti-Helicobacter pylori concomitant therapy and probiotic supplementation on the throat and gut microbiota in humans

Microbial Pathogenesis

Volumn 109, Issue , 2017, Pages 156-161

  Wang, Zi Juan ^a   Chen, Xiao Feng ^a   Zhang, Zi Xiao ^a   Li, Yu Chen ^a   Deng, Juan ^a   Tu, Jing ^a   Song, Zhi Qiang ^b   Zou, Qing Hua ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Antibiotic resistance; Concomitant therapy; Microbiota; Probiotic

Indexed keywords

AMOXICILLIN; BIOFLOR; CLARITHROMYCIN; ESOMEPRAZOLE; PROBIOTIC AGENT; TINIDAZOLE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEROIDES; BIFIDOBACTERIUM; CLINICAL ARTICLE; CONTROLLED STUDY; DEFECATION HABIT; DOUBLE BLIND PROCEDURE; ENTEROBACTERIACEAE; ENTEROCOCCUS; ERADICATION THERAPY; HELICOBACTER INFECTION; HUMAN; INTESTINE FLORA; LACTOBACILLUS; MICROFLORA; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SACCHAROMYCES BOULARDII; SIDE EFFECT; THROAT MICROBIOTA; ADOLESCENT; ADULT; AGED; COMBINATION DRUG THERAPY; DRUG EFFECTS; FECES; GASTROINTESTINAL TRACT; HELICOBACTER PYLORI; MICROBIOLOGY; MIDDLE AGED; PHARYNX; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEROIDES; DOUBLE-BLIND METHOD; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; ENTEROCOCCUS; FECES; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MIDDLE AGED; PHARYNX; PROBIOTICS; SACCHAROMYCES BOULARDII; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85019990471     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2017.05.035     Document Type: Article

References (40)

1. Fujimura, K.E., Slusher, N.A., Cabana, M.D., Lynch, S.V., Role of the gut microbiota in defining human health. Expert Rev. Anti Infect. Ther. 8 (2014), 435–454.
2. Sekirov, I., Russell, S.L., Antunes, L.C., Finlay, B.B., Gut microbiota in health and disease. Physiol. Rev. 90 (2010), 859–904.
3. Sun, J., Chang, E.B., Exploring gut microbes in human health and disease: pushing the envelope. Genes & Dis. 1 (2014), 132–139.
4. Delahay, R.M., Massimo, R., Pathogenesis of Helicobacter pylori infection. Helicobacter 17:Suppl 1 (2012), 9–15.
5. Suerbaum, S., Michetti, P., Helicobacter pylori infection. Clin. Microbiol. Infect. 347 (2002), 602–610.
6. Malfertheiner, P., Megraud, F., O'Morain, C.A., Gisbert, J.P., Kuipers, E.J., Axon, A.T., et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus report. Gut 66:1 (2017), 6–30 (Epub on 2016 Oct 5).
7. Megraud, F., Coenen, S., Versporten, A., Kist, M., Lopez-Brea, M., Hirschl, A., et al. Helicobacter pylori resistance to antibiotics in europe and its relationship to antibiotic consumption. Gut 62 (2013), 34–42.
8. Graham, D.Y., Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 59 (2010), 1143–1153.
9. Essa, A.S., Kramer, J.R., Graham, D.Y., Treiber, G., Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter 14 (2009), 109–118.
10. Gisbert, J.P., Calvet, X., Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment. Pharmacol. Ther. 34 (2011), 604–617.
11. Das, R., Sureshkumar, S., Sreenath, G.S., Kate, V., Sequential versus concomitant therapy for eradication of Helicobacter Pylori in patients with perforated duodenal ulcer: a randomized trial. Saudi J. Gastroenterol. Off. J. Saudi Gastroenterol. Assoc. 22 (2016), 309–315.
12. Gisbert, J.P., Calvet, X., Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin. Exp. Gastroenterol. 5 (2012), 23–34.
13. Dang, Y., Reinhardt, J.D., Zhou, X., Zhang, G., The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS One, 9, 2014 e111030–e111030.
14. Dore, M.P., Goni, E., Mario, F.D., Is there a role for probiotics in Helicobacter pylori therapy?. Gastroenterol. Clin. North Am. 44 (2015), 565–575.
15. Zhu, R., Chen, K., Zheng, Y.Y., Zhang, H.W., Wang, J.S., Xia, Y.J., et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J. Gastroenterol. 20 (2014), 814–815.
16. Lu, C., Sang, J., He, H., Wan, X., Lin, Y., Li, L., et al. Probiotic supplementation does not improve eradication rate of Helicobacter pylori infection compared to placebo based on standard therapy: a meta-analysis. Sci. Rep., 6, 2016, 23522.
17. Zhang, M.M., Qian, W., Qin, Y.Y., He, J., Zhou, Y.H., Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J. Gastroenterol. 21 (2015), 4345–4357.
18. Sjölund, M., Wreiber, K., Andersson, D.I., Blaser, M.J., Engstrand, L., Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann. Intern. Med. 139 (2003), 483–487.
19. Jönsson, M., Qvarnström, Y., Engstrand, L., Swedberg, G., Clarithromycin treatment selects for persistent macrolide-resistant bacteria in throat commensal flora. Int. J. Antimicrob. Agents 25 (2005), 68–74.
20. Jakobsson, H., Wreiber, K., Fall, K., Fjelstad, B., Nyrén, O., Engstrand, L., Macrolide resistance in the normal microbiota after Helicobacter pylori treatment. Infect. Dis. 39 (2007), 757–763.
21. Jakobsson, H.E., Jernberg, C., Andersson, A.F., Sjölundkarlsson, M., Jansson, J.K., Engstrand, L., Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One, 5, 2010, e9836.
22. Bühling, A., Radun, D., Müller, W.A., Malfertheiner, P., Influence of anti- Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. Aliment. Pharmacol. Ther. 15 (2001), 1445–1452.
23. Cuadradolavín, A., Salcinescaviedes, J.R., Diazperez, A., Carrascosa, M.F., Ochagavía, M., Fernandezforcelledo, J.L., et al. First-line eradication rates comparing two shortened non-bismuth quadruple regimens against Helicobacter pylori: an open-label, randomized, multicentre clinical trial. J. Antimicrob. Chemother. 70 (2015), 2376–2381.
24. Molina-Infante, J., Lucendo, A.J., Angueira, T., Rodriguez-Tellez, M., Perez-Aisa, A., Balboa, A., et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment. Pharmacol. Ther. 41 (2015), 581–589.
25. McNicholl, A., Marin, A., Molina-Infante, J., Castro, M., Barrio, J., Ducons, J., et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 63 (2014), 244–249.
26. Molina–Infante, J., Romano, M., Fernandez–Bermejo, M., Federico, A., Gravina, A.G., Pozzati, L., et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 145 (2013), 121–128 e121.
27. Georgopoulos, S.D., Xirouchakis, E., Zampeli, E., Martinez-Gonzalez, B., Grivas, E., Spiliadi, C.C., et al. A randomised study comparing 10 Days concomitant and sequential treatments for the eradication of Helicobacter pylori, in a high clarithromycin resistance area. Gastroenterology, 148, 2015 S-422.
28. Georgopoulos, S.D., Xirouchakis, E., Martinez-Gonzalez, B., Sgouras, D.N., Spiliadi, C., Mentis, A.F., et al. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area. Helicobacter 18 (2013), 459–467.
29. Zullo, A., Scaccianoce, G., Francesco, V.D., Vannella, L., Ruggiero, V., Dambrosio, P., et al. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin. Res. Hepatol. Gastroenterol. 37 (2013), 647–650.
30. Hartemink, R., Rombouts, F.M., Comparison of media for the detection of bifidobacteria, lactobacilli and total anaerobes from faecal samples. J. Microbiol. Methods 36 (1999), 181–192.
31. Cremonini, F., Caro, S.D., Covino, M., Armuzzi, A., Gabrielli, M., Santarelli, L., et al. Effect of different probiotic preparations on anti- Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am. J. Gastroenterol. 97 (2002), 2744–2749.
32. Goli, Y.D., Moniri, R., Efficacy of probiotics as an adjuvant agent in eradication of Helicobacter pylori infection and associated side effects. Benef. Microbes, 2016, 1–10.
33. Adamsson, I., Nord, C.E., Lundquist, P., Sjöstedt, S., Edlund, C., Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J. Antimicrob. Chemother. 44 (1999), 629–640.
34. Stark, C., Adamsson, I., Edlund, C., Sjösted, S., Seensalu, R., Wikström, B., et al. Effects of omeprazole and amoxycillin on the human oral and gastrointestinal microflora in patients with Helicobacter pylori infection. J. Antimicrob. Chemother. 38 (1996), 927–939.
35. Macfarlane, G.T., Cummings, J.H., Probiotics, infection and immunity. Curr. Opin. Infect. Dis. 15 (2002), 501–506.
36. Forsythe, P., Bienenstock, J., Immunomodulation by commensal and probiotic bacteria. Immunol. Invest 39 (2010), 429–448.
37. Duman, D.G., Bor, S., Ozütemiz, O., Sahin, T., Oğuz, D., Iştan, F., et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication. Eur. J. Gastroenterol. Hepatol. 17 (2005), 1357–1361.
38. Kyriakos, N., Papamichael, K., Roussos, A., Theodoropoulos, I., Karakoidas, C., Smyrnidis, A., et al. A lyophilized form of Saccharomyces boulardii enhances the Helicobacter pylori eradication rates of omeprazole-triple therapy in patients with peptic ulcer disease or functional dyspepsia. Hosp. Chron. 8 (2013), 127–133.
39. Cindoruk, M., Erkan, G., Karakan, T., Dursun, A., Unal, S., Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti- Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 12 (2007), 309–316.
40. Szajewska, H., Horvath, A., Piwowarczyk, A., Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment. Pharmacol. Ther. 32 (2010), 1069–1079.